

# YEAR-END REPORT Q4 2024 OCTOBER - DECEMBER

### Summary of the period

" Topline sales sprint in the last quarter crowns a successful year "

Net sales during the fourth quarter amounted to SEK 57,804 (25,273) thousand, which corresponds to an increase in sales of 129 (-16) % compared to the same quarter in 2023. The operating profit amounted to SEK 16,763 (-479) thousand.

Net sales for the full year 2024 amounted to SEK 179,451 (120,861) thousand, corresponding to an increase in sales of 48 (45) % compared to the full year 2023. The operating profit amounted to SEK 45,490 (23,389) thousand.

#### Significant events January to December 2024

- Major marine coating company launched a low biocidal premium antifouling product using Selektope.
- Sales of Selektope reached the 20 mt milestone with strong growth in NE Asia
- In conjunction with the Annual General meeting in May Philip Chaabane stepped down as CEO of I-Tech AB and was elected new Chairman of the board, replacing Stefan Sedersten. Remaining board was re-elected.
- The process for renewed approval within the EU moved from a scientific evaluation phase to a decision phase, and during the fall a Public Consultation was executed.
- Mid-September Markus Jönsson took office as CEO in I-Tech AB, replacing Magnus Henell who was serving as acting CEO since mid-May.
- I-Tech AB was awarded DI Gasell company by Dagens Industri.
- The board proposes an ordinary dividend of SEK 1.00 per share and en extra dividend of SEK 0.75 per share, in total SEK 1.75 per share, corresponding to 53% of the net profit for the year.

#### Significant events after the end of the period

I-Tech AB signed a supply and license agreement with major Asian-based paint company.

### **Financial summary**

All amounts in kSEK	2024 Oct-Dec	2023 Oct-Dec	2024 Jan-Dec	2023 Jan-Dec
Net sales	57,804	25,273	179,451	120,861
Operating result	16,763	-479	45,490	23,389
EBITDA	18,821	1,542	53,713	31,371
Net result	14,299	-233	39,013	20,203
Operating cash flow	6,173	-774	35,173	35,143
Equity at end of period	157,388	136,238	157,388	136,238
Cash and cash equivalents at end of period	100,164	83,262	100,164	83,262

### **CEO** Comments

2024 has been another record year for I-Tech. We signed supply agreements with two new global paint companies, total sales grew by 48% year-on-year, and our financial performance continued to improve, despite a significant increase in external costs linked to regulatory compliance. Operating profit (EBIT) for the year grew by 94%, reaching SEK 45.5 (23.4) million.

Selektope sales accelerated further in Q4, achieving a new quarterly record of SEK 57,8 (25,3) million. Total sales for the year amounted to SEK 179,5 (120,9) million, resulting in a net profit margin of 22% (17%). I-Tech has now repaid all loans and consumed all tax losses that have been carried forward since the start.

In 2023, CMP represented around 80% of total sales. Throughout this year, our sales have diversified, and now more than a third of total sales come from customers other than CMP. PPG launched Nexeon 810, a copper-free antifouling product with Selektope during the spring of 2024, and sales to them have grown substantially throughout the year. The share of total sales to Asia grew to 97% (92%), and year-on-year sales to Korea, Japan and China grew by 86%, 37% and 94%, respectively.

Selektope's Renewed Regulatory Approval in the EU:

The public consultation phase ended in November, with many external stakeholders voicing their concerns and disagreements with ECHA's opinion on the hazard profile of medetomidine and the Analysis of Alternatives conducted by Norway, the competent authority evaluating the dossier. An independent socioeconomic study commissioned by I-Tech concluded that non-renewal would have major disproportionate negative impacts on society, justifying renewal under derogation criteria.

In the next phase, EU Commission representatives will consider the input and engage the Standing Committee on Biocidal Products (SCPB), with a derogated approval being one potential outcome. A decision is likely to come during the second half of 2025.



#### Market expansion:

As previously highlighted, the dry-docking market segment is becoming increasingly accessible thanks to a broader customer base, excellent formulation development by the R&D team, and successful testing. These factors can further accelerate Selektope's growth in the coming years.

Regulatory approval processes in the USA are moving into a phase of higher activity in 2025, with the first steps of market penetration in the Americas expected this year. We are also expecting the regulatory process in New Zeeland and Malaysia to move forward during 2025.

A portfolio of new opportunities has been defined, and business development activities are being pursued in parallel with organic innovation projects. The team's capabilities related to specific activities are being strengthened by additional, flexible resources.

### Markus Jönsson

CEO I-Tech


### **Business and structure**

I-Tech AB (publ) is a biotech company active in Since the listing on Nasdag First North Growth the materials and chemical sector. The company develops and sells the product Selektope, an active ingredient to counteract marine growth used in coating systems for the commercial shipping industry. The company's business is primarily focused on antifouling coatings, although development is also taking place to potentially financial position, clear investments have been prevent marine growth in functional materials such as polyurethane. The company's customers are the leading global marine coating companies. Asia is the dominant market.

I-Tech owns the rights to Selektope and has the necessary manufacturing expertise. The company was founded in 2000 as a spin-off company from the University of Gothenburg and Chalmers University of Technology, and is now located at GoCo Health Innovation City in Mölndal, just south of Gothenburg in Sweden.

in 2018, the company has grown both customerwise and financially. The market is dominated by nine major paint companies where nearly all work actively with the company's technology. Six of them are commercially active and the others are in the development stage. Thanks to a continued stable made in the core business. Within the regulatory area, the geographical coverage is increased step by step at the same time as upgrades and renewals of existing approvals are required at regular intervals. The company also invests in research and development in line with the strategy of offering a higher level of knowledge about Selektope's formulation properties in antifouling coatings. The continuous improvement work has also led to an increased delivery capacity and efficiency in the production chain.

### **Rolling twelve-month turnover**



#### 2024 was a year of growth and dedication, leading to strong results!

The company achieved net sales of SEK 179,451 thousand, marking a 48% increase compared to 2023. The operating profit reached SEK 45,490 thousand, showcasing a significant improvement from the previous year. We also achieved a net profit margin of 22%.

### Other information

#### Share information

At the start of 2024, I-Tech's share capital amounted to SEK 23 816 914 distributed across 11 908 457 shares. The ratio value of all the shares amounts to SEK 2 and they have equal rights in the company's assets and profit/loss. I-Tech's shares were listed on the Nasdag First North Growth Market at Nasdaq Stockholm as of 29 May 2018.

As of 30 December 2024, the number of shareholders amounted to 2,430 (2,591). With a closing price for the share on 30 December 2024 of SEK 58.0 (55.2), the company's market capitalisation amounted to SEK 691 (657) million.

#### **Risk factors**

The company's risks are primarily related to the market development of Selektope. production risks related to partners' production and production capacity, as well as risks in regulatory permissions, other intangible assets and product development. For a more detailed description of significant risks and uncertainty factors, please see I-Tech's prospectus, which was published in conjunction with the public offering and the company's annual report for 2023.

#### Certified Adviser

I-Tech has engaged Carnegie Investment Bank as the Certified Adviser on First North at Nasdag Stockholm.

#### Long-term incentive programs

The Annual General Meeting 2022 adopted a long-term incentive program for management and other staff in the form of warrants. The program amounted to a maximum of 89,320 shares, of which all were issued and paid for.

- Avan
- Fonte IBKR
- Alcur
- Öhma
- Other Total

The warrants may lead to a dilution of a maximum of 0.8%. The exercise price is SEK 46.01 per share. Each warrant gives the right to acquire one share.

#### Audit review

This report has not been reviewed by the company's auditors.

#### List of stakeholders

The list of stakeholders shows the status in the company as of 30 December 2024.

#### Largest owners

Owner	No. of shares	Share capital %
Pomona-gruppen	1,756,417	14.75%
Futur pension	995,794	8.36%
Swedbank Robur	932,500	7.83%
Handelsbanken Funds	725,000	6.09%
Second Swedish National Pension Fund	643,400	5.40%
NEA Partners	624,000	5.24%
UBS AG	534,155	4.49%
Nordnet pension	489,218	4.11%
Unionen	450,000	3.78%
Stefan Sedersten incl. Companies	441,330	3.71%
Avanza pension	408,325	3.43%
Fontenelles Holding	348,831	2.93%
IBKR Financial Services	204,221	1.71%
Alcur Funds	179,442	1.51%
Öhman Funds	179,070	1.50%
Others	2,996,754	25.16%
Total shares	11.908.457	100.00%

### **Financial information**

#### Turnover and profit/loss

Sales for the period amounted to SEK 57,804 (25,273) thousand, which gives a net sales increase with 129% (-16%) and adjusted for currency effects, this corresponds to a growth with approx. 120%. The development is foremost a result of strong growth during the period in Korea and ends a great year with a total growth of 48% (45%).

The gross margin for the period shows a slight improvement compared to the previous year, 54 (52) % as an effect of the efforts made in the area. In the coming periods, the gross margin is expected to be further strengthened by a few percentage points.

Other external costs show a significant increase mainly due to activities around the re-registration of the company's EU BPR approval. The increase in personnel costs is in line with the reinforcements the company has made on the personnel side as well as an effect of a strong outcome in the personnel bonus program after a successful year.

With the strong turnover increase as a basis, which is further strengthened by the improved gross margin, the company shows a strong EBITDA, despite increased operating costs, amounting to SEK 16,763 (-479) thousand.

During the period, the remaining tax loss carry-forwards were utilized, which means that parts of the profit for the period and any profit in future periods will be subject to both an accounting and cash-impacting tax effect.

#### Cash flow

The cash flow from operating activities for the period amounted to SEK 6,173 (-774) thousand where the earnings amount to SEK 20,551 (1,759) thousand and the working capital amounts to SEK -14,378 (-2,533 thousand.

During the period, I-Tech invested SEK -273 (-557) thousand in fixed assets. Net SEK 0 (0) thousand has been deducted from the cash flow as the company has completed all obligations in connection with previous loans from the Energy Agency. This gives a total cash flow for the period of SEK 5,900 (-1,331) thousand.

#### **Financial summary**

Cash and cash equivalents in the company at the end of the period amounted to SEK 100,164 (83,262) thousand and equity amounted to SEK 157,388 (136,238) thousand. The change in cash and cash equivalents and equity is directly related to the company's results and other operating changes.

#### Principles of preparation

The accounts in this report have been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated accounts (K3). The principles of preparation are described in more detail in the company's annual report for the financial year 2023.

### **Income statement**

Amounts in kSEK	2024 Oct-Dec	2023 Oct-Dec	2024 Jan-Dec	2023 Jan-Dec
Operating income, etc.				
Net sales	57,804	25,273	179,451	120,861
Other operating income	1,424	382	2,325	2,154
	59,228	25,655	181,776	123,015
Cost of goods sold	-26,516	-12,175	-84,228	-57,324
Other external costs	-6,140	-4,681	-22,185	-15,293
Personnel expenses	-6,720	-5,733	-17,767	-15,827
Depreciations, amortizations and impairments	-2,058	-2,021	-8,223	-7,982
Other operating expenses	-1,031	-1,524	-3,883	-3,200
	-42,465	-26,134	-136,286	-99,626
Operating income	16,763	-479	45,490	23,389
Financial items				
Interest income and similar items	1,287	1,027	3,724	3,154
Interest expense and similar items	-	-792	-38	-1,049
	1,287	235	3,686	2,105
Result after financial items	18,050	-244	49,176	25,494
Tax on result from the year	-3,751	11	-10,163	-5,291
NET RESULT	14,299	-233	39,013	20,203

### **Upcoming financial reports**

11 April 2025	Annual report 2024
8 May 2025	Interim report, quarte
22 August 2025	Interim report, quarte
17 October 2025	Interim report, quarte

### **Balance** sheet

Amounts in kSEK	2024 Dec-31	2023 Dec-31
ASSETS		
Intangible assets	22,731	30,120
Tangible assets	2,394	2,820
Deferred tax assets	-	9,332
Total fixed assets	25,125	42,272
Inventory	4,067	4,280
Short-term receivables	43,758	22,629
Cash and bank balances	100,164	83,262
Total current assets	147,989	110,171
Total assets	173,114	152,443
Total assets EQUITY AND LIABILITIES	173,114	152,443
	<b>173,114</b> 23,817	<b>152,443</b> 23,817
EQUITY AND LIABILITIES	-	
EQUITY AND LIABILITIES Share capital	23,817	23,817
EQUITY AND LIABILITIES Share capital Restricted equity	23,817	23,817
EQUITY AND LIABILITIES Share capital Restricted equity Unrestricted equity	23,817 1,545 93,013	23,817 1,482 90,736
EQUITY AND LIABILITIES Share capital Restricted equity Unrestricted equity Result	23,817 1,545 93,013 39,013	23,817 1,482 90,736 20,203
EQUITY AND LIABILITIES Share capital Restricted equity Unrestricted equity Result Total equity	23,817 1,545 93,013 39,013 157,388	23,817 1,482 90,736 20,203 136,238

## Cash-flow analysis

Amounts in kSEK	2024 Oct-Dec	2023 Oct-Dec	2024 Jan-Dec	2023 Jan-Dec
Operating activities				
Operating result	16,763	-479	45,490	23,389
Adjustments for non-cash items	2,058	2,021	8,223	7,982
Interest received	1,644	999	3,806	2,896
Interest paid	-	-792	-38	-1,049
Income tax paid/received	86	10	28	-42
Changes in working capital				
Change in inventories	1,613	80	213	-1,867
Change in operating receivables	-10,150	-3,163	-21,211	-5,294
Change in operating liabilities	-5,841	550	-1,338	9,128
Cash flow from operating activities	6,173	-774	35,173	35,143
Investment activities				
Investments in non-current assets	-273	-557	-408	-2,383
Cash flow from investment activities	-273	-557	-408	-2,383
Financing activities				
Amortization/issue loan	-	-	-	-2,252
Dividend to shareholders	-	-	-17,863	-
Cash flow from financing activities	-	-	-17,863	-2,252
The period's cash flow	5,900	-1,331	16,902	30,508
Cash and cash equivalents at beginning of period	94,264	84,593	83,262	52,754
Cash and cash equivalents at end period	100,164	83,262	100,164	83,262
Adjustments for non-cash items				
Depreciation and amortizations	2,058	2,021	8,223	7,982
Other items not affecting cash flow	-	-	-	-
	2,058	2,021	8,223	7,982

### Equity changes

All amounts in kSEK	Restricted equity			Unrestric	Total equity	
	Share capital	Statutory reserve	Development expense fund	Share premium reserve	Other unrestric- ted equity	
2023-01-01	23,817	753	775	143,276	-52,586	116,035
Capitalization of develop- ment expenses	-	-	-46	-	46	-
Net result for the year	-	-	-	-	20,203	20,203
2023-12-31	23,817	753	729	143,276	-32,337	136,238
2024-01-01	23,817	753	729	143,276	-32,337	136,238
Dividend to shareholders	-	-	-	-	-17,863	-17,863
Capitalization of develop- ment expenses	-	-	63	-	-63	-
Net result for the period	-	-	-	-	39,013	39,013
2024-12-31	23,817	753	792	143,276	-11,250	157,388

### **Financial ratios**

	2024 Oct-Dec	2023 Oct-Dec	2024 Jan-Dec	2023 Jan-Dec
Turnover growth %	129%	-16%	48%	45%
Gross margin %	54%	52%	53%	53%
Operating margin %	29%	-2%	25%	19%
Profit margin %	25%	-1%	22%	17%
Solidity	91%	89%	91%	89%
Cash liquidity	915%	653%	653%	745%
Return on average total capital	11%	0%	30%	18%
Return on average total equity	12%	0%	33%	20%
Average of outstanding shares	11,908,457	11,908,457	11,908,457	11,908,457
Outstanding shares end of period	11,908,457	11,908,457	11,908,457	11,908,457
Result per share	1.2	0.0	3.3	1.7
Result per share fully diluted	1.2	0.0	3.3	1.7
Equity per share	13.2	11.4	13.2	11.4
Equity per share fully diluted	13.1	11.3	13.1	11.3
Dividend per share	-	-	1.5	-

#### **DEFINITIONS OF KEY FIGURES**

#### Net sales growth

The percentage increase in sales for the past period compared with the corresponding previous period.	
<b>Gross margin</b> Gross profit for the period in relation to the period's net sales.	
<b>Gross profit</b> Net sales of the period decreased by raw materials and supplies.	
<b>Operating margin</b> Operating income for the period in relation to the period's net sales. <b>Profit margin</b>	

Profit for the period in relation to the period's net sales.

#### Solidity

Shareholders' equity as a percentage of total assets.

#### **Cash liquidity**

Current assets, excluding inventories, in relation to current liabilities, without adjustment for proposed dividend.

#### Return on average total capital

Net profit for the period, as a percentage of average total capital.

#### Return on average total equity

Net profit for the period, as a percentage of average shareholders' equity.

#### Result per share

Profit for the period divided by the average number of outstanding shares during the year.

#### Equity per share

Total equity divided by the number of shares at the end of the period.

The board and the managing director assures that the interim report provides a fair overview of the Company's position and results

Mölndal 6 February 2025

Philip Chaabane, Chairman of the board Mikael Laurin, Member of the board Tomas Tedgren, Member of the board Chatarina Schneider, Member of the board Tomas Bergdahl, Member of the board Raouf Kattan, Member of the board Markus Jönsson, Chief Executive Officer

#### Address

I-Tech AB GoCo Health Innovation City Förändringens gata 10 SE 431 53 Mölndal Tel: 010-3303999 org.nr: 556585-9682

www.i-tech.se

#### Contact

Markus Jönsson, CEO Tel: +46(0)72 977 96 25 markus.jonsson@i-tech.se